Figure 3.

Stabilisation of cytokeratin (CK) expression by PlGF, with disruption by BP-1. (A) CK19 expression in MDA-MB-231 pre-treated with PlGF before adding actinomycin D (ActD) or CHX vs either inhibitor alone (n=2 experiments each treatment). (B) Upper panel: representative blot showing MDA-MB-231 CK19 expression following treatment with ActD (1 μg ml⁻¹) or CHX (3 μg ml⁻¹) alone. (30-min, 1-, and 3-h time points are shown: Un, untreated; P, PlGF-only; A, ActD; C, CHX at each time point.) Lower panel: representative blot showing CK19 expression when cells were pre-treated with PlGF 15 min before adding ActD or CHX. (30 min, 1 or 3 h after inhibitor was added: Un, untreated; P, PlGF-only; P/A, PlGF pre-treated, followed by ActD; P/C, PlGF pre-treated, followed by CHX for the times indicated.)